Understanding the Market | LUYE PHARMA fell nearly 15% after earnings, with full-year net profit down 11% and tumor product sales decreasing by 1.8%

LUYE PHARMA fell nearly 15% after its earnings report, as of the time of publication, it dropped 14.11%, trading at HKD 2.13, with a transaction volume of HKD 274 million. In terms of news, LUYE PHARMA released its annual performance report, with revenue of RMB 6.061 billion, a year-on-year decrease of 1.33%; profit attributable to shareholders was RMB 472 million, a year-on-year decrease of 11.4%; basic earnings per share were 12.54 cents. No final dividend was declared. During the reporting period, the sales of products in the central nervous system treatment field decreased by 4.8%, reaching RMB 1.613 billion. Sales of products in the oncology treatment field decreased by 1.8%, reaching RMB 2.085 billion. Sales of products in the cardiovascular system treatment field decreased by 1.6%, reaching RMB 1.660 billion. Sales of products in the metabolic treatment field decreased by 13.7%, reaching RMB 389 million